Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

    ... refractory anemia with excess blasts (RAEB), RAEB in transformation, or chronic myelomonocitic leukaemia ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Tea consumption reduces the risk of de novo myelodysplastic syndromes

    ... in the refractory anemia with excessive blasts subtype, in cytogenetic 'good' and 'intermediated/poor' prognosis ...

    Research Article last updated 01/20/2015 - 12:56pm.

  3. Personalized medicine for MDS

    ... who does not require transfusions, has no increase in blasts , nor any poor-risk cytogenetic abnormalities. These patients, ...

    Research Review last updated 05/02/2016 - 9:44am.

  4. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

    ... high-risk refractory anemia with excess blasts (RAEB) stages of MDS, the GMP population is increased in frequency ...

    Research Article last updated 03/05/2013 - 9:20am.

  5. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.

    ... , those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... At diagnosis, 126 patients (77%) had an excess of marrow blasts , and 95 patients (58%) had intermediate-2 or high-risk MDS according ...

    Research Article last updated 11/05/2012 - 8:57am.

  7. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

    ... of refractory anemia with excess blasts (RAEB)-1 were independent prognostic factors for AML progression ...

    Research Article last updated 03/05/2013 - 9:29am.

  8. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... subtypes refractory anaemia with excess blasts (RAEB) and RAEB in transformation. When analyzed per patient year ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes

    ... anemia or refractory anemia with excess blasts ). The magnitude of the cost of care underscores a need for ...

    Research Article last updated 10/01/2012 - 9:41am.

  10. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... and high risk scores including WHO-defined AML (20-30% blasts ) who cannot proceed immediately to allogeneic stem cell ...

    Research Article last updated 10/11/2011 - 5:58pm.